AU2005204365A1 - Compositions comprising memantine and polyanionic polymers for administration to the eye - Google Patents

Compositions comprising memantine and polyanionic polymers for administration to the eye Download PDF

Info

Publication number
AU2005204365A1
AU2005204365A1 AU2005204365A AU2005204365A AU2005204365A1 AU 2005204365 A1 AU2005204365 A1 AU 2005204365A1 AU 2005204365 A AU2005204365 A AU 2005204365A AU 2005204365 A AU2005204365 A AU 2005204365A AU 2005204365 A1 AU2005204365 A1 AU 2005204365A1
Authority
AU
Australia
Prior art keywords
component
eye
adamantane
composition
memantine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005204365A
Other languages
English (en)
Inventor
Patrick M. Hughes
Orest Olejnik
Rhett Schiffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/752,125 external-priority patent/US20050147584A1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2005204365A1 publication Critical patent/AU2005204365A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005204365A 2004-01-05 2005-01-04 Compositions comprising memantine and polyanionic polymers for administration to the eye Abandoned AU2005204365A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/752,125 US20050147584A1 (en) 2004-01-05 2004-01-05 Compositions and methods comprising memantine and polyanionic polymers
US10/752,125 2004-01-05
US10/941,272 US20050031652A1 (en) 2003-02-25 2004-09-14 Compositions and methods comprising memantine and polyanionic polymers
US10/941,272 2004-09-14
PCT/US2005/000249 WO2005067891A1 (en) 2004-01-05 2005-01-04 Compositions comprosing memantine and polyanionic polymers for administration to the eye

Publications (1)

Publication Number Publication Date
AU2005204365A1 true AU2005204365A1 (en) 2005-07-28

Family

ID=34798997

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005204365A Abandoned AU2005204365A1 (en) 2004-01-05 2005-01-04 Compositions comprising memantine and polyanionic polymers for administration to the eye

Country Status (7)

Country Link
US (1) US20050031652A1 (cg-RX-API-DMAC10.html)
EP (1) EP1701700A1 (cg-RX-API-DMAC10.html)
JP (1) JP2007517885A (cg-RX-API-DMAC10.html)
AU (1) AU2005204365A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0506689A (cg-RX-API-DMAC10.html)
CA (1) CA2552521A1 (cg-RX-API-DMAC10.html)
WO (1) WO2005067891A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293737B2 (en) 2006-10-16 2012-10-23 Bionomics Limited Anxiolytic compounds
US9023848B2 (en) 2011-03-02 2015-05-05 Bionomics Limited Small-molecules as therapeutics
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
US20080033053A1 (en) * 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
JP2008507588A (ja) * 2004-07-26 2008-03-13 アラーガン、インコーポレイテッド 眼の病態を処置する方法
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
WO2008098027A2 (en) * 2007-02-06 2008-08-14 Allergan, Inc. Treatment of ischemic retinal conditions with memantine
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5691316A (en) * 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
AU761824B2 (en) * 1998-10-27 2003-06-12 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
CA2368242A1 (en) * 1999-03-12 2000-09-21 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US6482854B1 (en) * 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
SK282717B6 (sk) * 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US6761694B2 (en) * 2001-12-13 2004-07-13 Allergan, Inc. Methods for measuring retinal damage
US6982079B2 (en) * 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
EP1654002B2 (en) * 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293737B2 (en) 2006-10-16 2012-10-23 Bionomics Limited Anxiolytic compounds
US8551990B2 (en) 2006-10-16 2013-10-08 Bionomics Limited Anxiolytic compounds
US8614212B2 (en) 2006-10-16 2013-12-24 Bionomics Limited Anxiolytic compounds
US8906912B2 (en) 2006-10-16 2014-12-09 Bionomics Limited Anxiolytic compounds
US9573945B2 (en) 2006-10-16 2017-02-21 Bionomics Limited Anxiolytic compounds
US9975892B2 (en) 2006-10-16 2018-05-22 Bionomics Limited Anxiolytic compounds
US10233181B2 (en) 2006-10-16 2019-03-19 Bionomics Limited Anxiolytic compounds
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
US9023848B2 (en) 2011-03-02 2015-05-05 Bionomics Limited Small-molecules as therapeutics
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines

Also Published As

Publication number Publication date
WO2005067891A1 (en) 2005-07-28
JP2007517885A (ja) 2007-07-05
US20050031652A1 (en) 2005-02-10
BRPI0506689A (pt) 2007-05-02
CA2552521A1 (en) 2005-07-28
EP1701700A1 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
US12409175B2 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
US8299124B2 (en) Aqueous intraocular penetration-promoting eye drop
RU2744570C2 (ru) Фармацевтическая композиция на основе трамадола для офтальмологического применения
KR20080011310A (ko) 폴록사머 또는 메록사폴 계면활성제 및 글리콜을유효성분으로 함유하는 현탁제, 안질환 치료용 의약의제조를 위한 그의 용도
KR20160126983A (ko) 안내 혈관신생 및/또는 누출 치료용 조성물 및 방법
CN103747786A (zh) 比马前列素和溴莫尼定的固定剂量组合
MX2014012158A (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
AU2006244245B2 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
US20050031652A1 (en) Compositions and methods comprising memantine and polyanionic polymers
JP2005533087A (ja) 神経損傷の処置にリアノジン拮抗剤を用いる方法
CA3001957C (en) Ophthalmic solution of difluprednate
EP3749294A1 (en) Formulations comprising chelators, permeation enhancers and hydroxyethyl cellulose for treating ophthalmic disorders
JPH06316519A (ja) 薬剤で誘導される瞳孔拡大を抑制し又は拡大された瞳孔を 縮小するための、一定のスルファモイル置換フェネチルア ミン誘導体の使用、及びそれに用いる局部的投与組成物
JP2008517937A (ja) 眼科用組成物及びその使用方法
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
US20050277698A1 (en) Memantine delivery to the back of the eye
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
US20050147584A1 (en) Compositions and methods comprising memantine and polyanionic polymers
JP2024501425A (ja) 眼炎症の有害作用を軽減するためのジフルプレドナート
WO2025040941A1 (en) Ophthalmic pharmaceutical compositions containing dorzolamide, methods for their preparation, and for their use
EP0607697A2 (en) DILAZEP for reduction of elevated intraocular pressure
CA3036474A1 (en) Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor
HK40029199A (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
JPH02255618A (ja) 緑内障治療剤
HK1174858A (en) Ophthalmic formulations containing substituted gamma lactams and methods for use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOSITIONS COMPRISING MEMANTINEAND POLYANIONIC POLYMERS FOR ADMINISTRATION TO THE EYE

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application